Vandria SA has announced a series A financing round raising $20.6 million (CHF18 million) to help advance its pipeline of first-in-class small-molecule mitophagy inducers.
Vaccines provide a front-line defense against dangerous viruses, training adaptive immune cells to identify and fight specific pathogens. But innate immune cells — the first responders to any bodily ...
– WTX-124 Phase 1/1b clinical trial on track for data readouts and interactions with the FDA in the second half of the year – – First patient dosed in the Phase 1b/2 clinical trial of WTX-330, seeking ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback